Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124119323 | 12411932 | 3 | F | 2016 | 20160722 | 20160527 | 20160729 | EXP | FR-PFIZER INC-2016269607 | PFIZER | 75.00 | YR | M | Y | 56.00000 | KG | 20160729 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124119323 | 12411932 | 1 | PS | TAHOR | ATORVASTATIN CALCIUM | 1 | Oral | 80 MG, 1X/DAY | 400 | MG | Y | 20702 | 80 | MG | QD | ||||
| 124119323 | 12411932 | 2 | SS | TAHOR | ATORVASTATIN CALCIUM | 1 | Oral | 80 MG, 2X/DAY | 400 | MG | Y | 20702 | 80 | MG | BID | ||||
| 124119323 | 12411932 | 3 | SS | TAHOR | ATORVASTATIN CALCIUM | 1 | Oral | 80 MG, 1X/DAY | 400 | MG | Y | 20702 | 80 | MG | QD | ||||
| 124119323 | 12411932 | 4 | SS | TAHOR | ATORVASTATIN CALCIUM | 1 | Oral | 80 MG, 2X/DAY | 400 | MG | Y | 20702 | 80 | MG | BID | ||||
| 124119323 | 12411932 | 5 | C | INEXIUM | ESOMEPRAZOLE | 1 | Oral | 20 MG, 1X/DAY | 0 | 20 | MG | GASTRO-RESISTANT TABLET | QD | ||||||
| 124119323 | 12411932 | 6 | C | KARDEGIC | ASPIRIN LYSINE | 1 | Oral | 75 MG, 1X/DAY | 0 | 75 | MG | POWDER FOR ORAL SOLUTION | QD | ||||||
| 124119323 | 12411932 | 7 | C | BRILIQUE | TICAGRELOR | 1 | Oral | 90 MG, 2X/DAY | 0 | 90 | MG | FILM-COATED TABLET | BID | ||||||
| 124119323 | 12411932 | 8 | C | BISOCE | BISOPROLOL | 1 | Oral | 1.25 MG, 2X/DAY | 0 | 1.25 | MG | FILM-COATED TABLET | BID | ||||||
| 124119323 | 12411932 | 9 | C | TRIATEC | RAMIPRIL | 1 | Oral | 1.25 MG, 2X/DAY | 15 | MG | 0 | 1.25 | MG | TABLET | BID | ||||
| 124119323 | 12411932 | 10 | C | TRIATEC | RAMIPRIL | 1 | Oral | 1.25 MG, 2X/DAY | 15 | MG | 0 | 1.25 | MG | TABLET | BID | ||||
| 124119323 | 12411932 | 11 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | UNK | 0 | ||||||||||
| 124119323 | 12411932 | 12 | C | MODOPAR | BENSERAZIDE HYDROCHLORIDELEVODOPA | 1 | Oral | 250 MG, 3X/DAY | 0 | 250 | MG | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124119323 | 12411932 | 1 | Prophylaxis |
| 124119323 | 12411932 | 12 | Parkinson's disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124119323 | 12411932 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124119323 | 12411932 | Accidental overdose | |
| 124119323 | 12411932 | Cholestasis | |
| 124119323 | 12411932 | Drug prescribing error | |
| 124119323 | 12411932 | Fall | |
| 124119323 | 12411932 | Liver injury | |
| 124119323 | 12411932 | Renal failure | |
| 124119323 | 12411932 | Rhabdomyolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124119323 | 12411932 | 1 | 20160221 | 20160225 | 0 | |
| 124119323 | 12411932 | 2 | 20160226 | 20160330 | 0 | |
| 124119323 | 12411932 | 3 | 20160330 | 20160408 | 0 | |
| 124119323 | 12411932 | 4 | 20160420 | 20160427 | 0 | |
| 124119323 | 12411932 | 5 | 20160221 | 0 | ||
| 124119323 | 12411932 | 6 | 20160221 | 0 | ||
| 124119323 | 12411932 | 7 | 20160221 | 0 | ||
| 124119323 | 12411932 | 8 | 20160221 | 0 | ||
| 124119323 | 12411932 | 9 | 20160221 | 20160408 | 0 | |
| 124119323 | 12411932 | 10 | 20160422 | 0 | ||
| 124119323 | 12411932 | 11 | 20160423 | 0 |